The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia.
- 1 minute agoClinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesyla
- 1 minute agoBinding of alpha-1-acid glycoprotein to imatinib following increased dosage of drug.
- 1 minute agoListeria monocytogenes meningitis following imatinib mesylate-induced monocytopenia in a patient with chronic myeloid leukemia.
- 1 minute agoMajor molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript.
- 1 minute agoThe role of P-glycoporotein in imatinib resistance.
- 1 minute agoThe NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance.
- 1 minute agoMobilization of Autologous Hematopoietic Progenitors and Subsequent Transplantation is a Safe and Feasible Procedure in Chronic Phase Chronic Myelogen
- 1 minute agoMyeloid leukemias and lung involvement.
- 1 minute ago
New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com
Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com
CML (Chronic Myelogenous Leukemia Support List)
---------------------------------
Part Of CMLHope.Com
An International Community Of CML Patients
For more information: http://cmlhope.com
Post Message: [email protected]
Subscribe: [EMAIL PROTECTED]
Unsubscribe: [EMAIL PROTECTED]
Change To No Mail/Web: [EMAIL PROTECTED]
Change To Digest: [EMAIL PROTECTED]
Change To Email: [EMAIL PROTECTED]
List Help: [EMAIL PROTECTED]
CML Group Web Site http://groups.yahoo.com/group/CML
YAHOO! GROUPS LINKS
- Visit your group "CML" on the web.
- To unsubscribe from this group, send an email to:
[EMAIL PROTECTED]
- Your use of Yahoo! Groups is subject to the Yahoo! Terms of Service.
